An open-label, multicenter biomarker-oriented phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
M Moehler, A Mueller, JT Hartmann, MP Ebert, SE Al-Batran, P Reimer, M Weihrauch, F Lordick, T Trarbach, S Biesterfeld, M Kabisch, D Wachtlin, PR Galle · Zeitschrift für Gastroenterologie · 2011 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: Tumour angiogenesis, growth, and metastasis can be inhibited by blocking receptor tyrosine kinases (RTKs) overexpressed in human advanced gastric cancer (AGC), including vascular endothelial growth factor receptors (VEGFRs), epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptors (PDGFRs). Sunitinib malate, an oral, multi-targeted tyrosine kinase inhibitor of VEGFR1, -2, and -3, PDGFR-α and -β, and several other related RTKs was investigated Sunitinib in pretreated patients with AGC. Preplanned analyses of tumour biomarkers on treatment outcome were performed. Patients an…
